[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609460":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NNC4005-0001","EXPERIMENTAL","Participants will receive a single dose of NNC4005-0001 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts.",[13],"Drug: NNC4005-001",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in each cohort will receive placebo matched to NNC4005-0001 injected subcutaneously.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","NNC4005-001","NNC4005-0001 will be given as a single ascending dose via subcutaneous route",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo matched to NNC4005-0001 will be given via subcutaneous route",[15],[31],{"name":32,"affiliation":5,"role":33},"Clinical Transparency' (dept. 2834)","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":26},"Altasciences Clinical Company, Inc","RECRUITING","Montreal","Quebec","H3P 3P1","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-73.58781,45.50884,{"lat":53,"lon":52},{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100609460","phase-1-a-research-study-of-a-potential-new-medicine-nnc4005-0001-for-liver-disease-in-adult-participants-with-increased-body-weight-and-liver-fat-100609460",false,"NCT07214870","A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NNC4005-0001 in Adults","Inclusion Criteria:\n\n* Aged 18-69 years (both inclusive) at the time of signing the informed consent.\n* Body Mass Index (BMI) of 27.0-40.0 kilogram per square meter (kg\u002Fm\\^2) (both inclusive) at screening process.\n* Hepatic fat fraction greater than or equal to (≥) 8% by magnetic resonance imaging proton density fat fraction (MRI-PDFF) within 17 days prior to dosing.\n* No prior or present clinical history of metabolic dysfunction-associated steatohepatitis (MASH) diagnosis.\n\nExclusion criteria:\n\n* Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Previous or current use of therapies for MASH or antifibrotic therapies (authorised or within aclinical trial).\n* Use of high-dose vitamin E \\[greater than (\\>) 800 international unit (IU) per day\\], glucagon-like peptide-1 (GLP-1) agonists (such as liraglutide, dulaglutide, or semaglutide), glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 agonists (such as tirzepatide), or pioglitazone within 6 months prior to screening.\n* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels greater than or equal (≥) 1.5× Upper Limit of Normal (ULN) at screening.\n* Total bilirubin levels \\> 1.5 times ULN if direct bilirubin is within Normal Limits (WNL) at screening.","ALL","18 Years","69 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1","The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.",[75],"Fatty Liver Disease","2026-02-09",{"date":78,"type":79},"2026-02-11","ACTUAL",{"date":81,"type":79},"2025-10-08",{"date":83,"type":69},"2027-05-14",{"name":5,"class":6},1]